PharmGKB:  The Pharmacogenetics and Pharmacogenomics Knowledge Base
Search PharmGKB:?
 

Important Variant Information for CYP2C19

Submitted by: Jason Robarge, Rebecca Fletcher, Anne Nguyen (COBRA), Caroline F. Thorn (PharmGKB)
Reviewed by: Under Review
Submitted date: September 30, 2006


There are Two Important Variants for CYP2C19.

  1. CYP2C19:636G>A
  2. CYP2C19:681G>A


1. CYP2C19:636G>A

Gene HGNC Name: CYP2C19
Variant Summary: The G>A change at position 636 in the cDNA results in a premature termination codon at amino acid 212 (W212X) [PMID: 7969038]. CYP2C19: 636G>A is the defining SNP of the CYP2C19*3 haplotype.
Key PubMed IDs: 7969038; 7586932
GoldenPath Position: Chr10:96530400  (hg18)
mRNA Variant & GenBank ID: G>A at 636 on NM_000769
Genomic Variant & GenBank ID: G>A at 19952 on AY796203.1
Protein Variant & GenBank ID: Trp>Ter at 212 on NP_000760
dbSNP rs#: rs4986893
Key Drugs/Substrates: lansoprazole; omeprazole; pantoprazole; rabeprazole; phenytoin; mephenytoin; phenobarbitone; amitriptyline; carisoprodol; citalopram; clomipramine; cyclophosphamide; hexobarbital; imipramine; indomethacin; mephobarbital; moclobemide; nelfinavir; nilutamide; primidone; progesterone; proguanil; propranolol; teniposide; warfarin
Key Phenotypes/Diseases: Phenotypes: Mephenytoin poor metabolizer (OMIM: 124020); Omeprazole poor metabolizer (OMIM: 124020); Proguanil poor metabolizer (OMIM: 124020)
Key Haplotypes CYP2C19*3


2. CYP2C19:681G>A

Gene HGNC Name: CYP2C19
Variant Summary: The CYP2C19:681G>A variant introduces a splicing defect altering the reading frame of the mRNA starting with amino acid 215 and produces a premature stop codon 20 amino acids downstream, which results in a truncated, non-functional protein responsible for the poor metabolizer phenotype [PMID: 8195181]. This SNP is the defining SNP of the CYP2C19*2 haplotype.
Key PubMed IDs: 8195181; 9732415
GoldenPath Position: Chr10:96531606  (hg18)
mRNA Variant & GenBank ID: G>A at 681 on NM_000769
Genomic Variant & GenBank ID: G>A at 21158 on AY796203.1
Protein Variant & GenBank ID: Pro>Pro at 227 on NP_000760
dbSNP rs#: rs4244285
Key Drugs/Substrates: lansoprazole; omeprazole; pantoprazole; rabeprazole; phenytoin; mephenytoin; phenobarbitone; amitriptyline; carisoprodol; citalopram; clomipramine; cyclophosphamide; hexobarbital; imipramine; indomethacin; mephobarbital; moclobemide; nelfinavir; nilutamide; primidone; progesterone; proguanil; propranolol; teniposide; warfarin
Key Phenotypes/Diseases: Phenotypes: Mephenytoin poor metabolizer (OMIM: 124020); Omeprazole poor metabolizer (OMIM: 124020); Proguanil poor metabolizer (OMIM: 124020)
Key Haplotypes CYP2C19*2
The PGRN is financially supported by grants from NIGMS, NHLBI, NHGRI, NIEHS, NCI, and NLM within the NIH, HHS. PharmGKB is managed at Stanford University. This work is supported by the NIH/NIGMS Pharmacogenetics Research Network and Database (U01GM61374). ©2001-2008 PharmGKB.